Robert Muga

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/622790/publications.pdf

Version: 2024-02-01

141 2,727 papers citations

26 h-index 45 g-index

159 all docs

159 docs citations 159 times ranked 3615 citing authors

#	Article	IF	CITATIONS
1	Alcoholic Liver Disease Among Patients with Wernicke Encephalopathy: A Multicenter Observational Study. Drug and Alcohol Dependence, 2022, 230, 109186.	1.6	9
2	Increased Natural Killer Cells Are Associated with Alcohol Liver Fibrosis and with T Cell and Cytotoxic Subpopulations Change. Journal of Clinical Medicine, 2022, 11, 305.	1.0	7
3	Abuse Potential of Cathinones in Humans: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 1004.	1.0	13
4	Prevalence and associations of metabolic syndrome in patients with alcohol use disorder. Scientific Reports, 2022, 12, 2625.	1.6	10
5	New Synthetic Opioids Use among Patients in Treatment for an Opioid Use Disorder in Barcelona. European Addiction Research, 2022, 28, 323-330.	1.3	3
6	New Psychoactive Substances Consumption in Opioid-Use Disorder Patients. Biology, 2022, 11, 645.	1.3	2
7	Plasma Amino Acid Concentrations in Patients with Alcohol and/or Cocaine Use Disorders and Their Association with Psychiatric Comorbidity and Sex. Biomedicines, 2022, 10, 1137.	1.4	0
8	Utilización de opioides para el dolor crónico no oncológico. Respuesta. Medicina ClÃnica, 2021, 156, 98-99.	0.3	0
9	Long-Term Outcomes of Patients With Cocaine Use Disorder: A 18-years Addiction Cohort Study. Frontiers in Pharmacology, 2021, 12, 625610.	1.6	7
10	Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment. Aids, 2021, 35, 1283-1293.	1.0	13
11	Late presentation for HIV remains a major health issue in Spain: Results from a multicenter cohort study, 2004–2018. PLoS ONE, 2021, 16, e0249864.	1.1	25
12	Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study. Journal of the International AIDS Society, 2021, 24, e25732.	1.2	14
13	Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use. World Journal of Gastroenterology, 2021, 27, 3223-3237.	1.4	2
14	Las otras dianas del trastorno por uso de alcohol: Afectaciones sistémicas derivadas del consumo excesivo de alcohol. Metode, 2021, , .	0.0	0
15	Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder. Scientific Reports, 2021, 11, 13629.	1.6	5
16	Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent singleâ€ŧablet regimen in a multicentre cohort in Spain. Journal of the International AIDS Society, 2021, 24, e25758.	1.2	1
17	COVIDâ€19 in hospitalized HIVâ€positive and HIVâ€negative patients: A matched study. HIV Medicine, 2021, 22, 867-876.	1.0	21
18	Markers of Monocyte Activation, Inflammation, and Microbial Translocation Are Associated with Liver Fibrosis in Alcohol Use Disorder. Journal of Clinical Medicine, 2021, 10, 3496.	1.0	2

#	Article	IF	CITATIONS
19	Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence. JAMA Psychiatry, 2021, 78, 979.	6.0	244
20	Use of opioids for chronic non-cancer pain. Reply. Medicina ClÃnica (English Edition), 2021, 156, 98-99.	0.1	0
21	Sex-specific Associations of Alcohol Withdrawal in Patients Admitted for the Treatment of Alcohol Use Disorder. Journal of Addiction Medicine, 2021, 15, 68-73.	1.4	8
22	Physicians' opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain. Journal of Antimicrobial Chemotherapy, 2020, 75, 466-472.	1.3	6
23	Significance of Markers of Monocyte Activation (CD163 and sCD14) and Inflammation (ILâ€6) in Patients Admitted for Alcohol Use Disorder Treatment. Alcoholism: Clinical and Experimental Research, 2020, 44, 152-158.	1.4	7
24	How well are we performing the initial assessment of HIVâ€positive patients? Results from a multicentre cohort in Spain. HIV Medicine, 2020, 21, 128-134.	1.0	0
25	Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. Lancet HIV,the, 2020, 7, e565-e573.	2.1	42
26	Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study. Journal of Antimicrobial Chemotherapy, 2020, 75, 3004-3014.	1.3	5
27	Association of hyperuricemia and gamma glutamyl transferase as a marker of metabolic risk in alcohol use disorder. Scientific Reports, 2020, 10, 20060.	1.6	8
28	Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. AIDS Research and Therapy, 2020, 17, 45.	0.7	1
29	Cannabis use is associated with monocyte activation (sCD163) in patients admitted for alcohol use disorder treatment. Drug and Alcohol Dependence, 2020, 216, 108231.	1.6	1
30	Loss of naive T lymphocytes is associated with advanced liver fibrosis in alcohol use disorder. Drug and Alcohol Dependence, 2020, 213, 108046.	1.6	12
31	MDMA interactions with pharmaceuticals and drugs of abuse. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 357-369.	1.5	19
32	Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study. World Journal of Gastroenterology, 2020, 26, 5874-5883.	1.4	4
33	DSM-5 en pacientes que solicitan el primer tratamiento del trastorno por uso de alcohol. Diferencias de sexo en el estudio multicéntrico CohRTA. Revista De Psicologia De La Salud, 2020, 32, 136.	0.2	6
34	Five‥ear Incidence of Hospitalâ€Based Emergencies Related to Acute Recreational Intoxication in Minors. Alcoholism: Clinical and Experimental Research, 2019, 43, 2179-2186.	1.4	2
35	Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors. PLoS ONE, 2019, 14, e0221598.	1.1	7
36	Meconium Biomarkers of Prenatal Alcohol Exposure. , 2019, , 585-594.		0

#	Article	IF	CITATIONS
37	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIVâ€positive individuals. Statistics in Medicine, 2019, 38, 2428-2446.	0.8	13
38	Riesgo de cáncer en personas con VIH en España, 2004-2015. Estudio de la cohorte CoRIS. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 502-508.	0.3	12
39	Liver Ultrasound Abnormalities in Alcohol Use Disorder. , 2019, , .		O
40	EP1.16-17 Management of Inappropriate Use of Opioids (IUO) in Patients (P) with Lung Cancer (LC). Journal of Thoracic Oncology, 2019, 14, S1070-S1071.	0.5	0
41	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. Aids, 2019, 33, 327-337.	1.0	5
42	HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors. BMC Medicine, 2019, 17, 4.	2.3	43
43	Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010–2015. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 580-587.	0.3	4
44	Key interindividual determinants in MDMA pharmacodynamics. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 183-195.	1.5	15
45	Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 329-337.	0.9	53
46	Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 102-109.	0.9	2
47	Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort. Aids, 2018, 32, 161-169.	1.0	19
48	Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. Aids, 2018, 32, 327-335.	1.0	13
49	Metabolic Syndrome among Individuals with Heroin use Disorders on Methadone Therapy: Prevalence, Characteristics, and Related Factors. Substance Abuse, 2018, 39, 46-51.	1.1	30
50	Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients. Medicine (United States), 2018, 97, e12238.	0.4	8
51	The opioid crisis. Medicina ClÃnica (English Edition), 2018, 151, 487-488.	0.1	1
52	Hepatitis C infection substantially reduces survival of alcohol-dependent patients. Clinical Epidemiology, 2018, Volume 10, 897-905.	1.5	7
53	Current Opioid Access, Use, and Problems in Central and Western European Jurisdictions. Current Addiction Reports, 2018, 5, 478-484.	1.6	2
54	Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder?. Drug and Alcohol Dependence, 2018, 188, 180-186.	1.6	6

#	Article	IF	CITATIONS
55	La crisis de los opioides. Medicina ClÃnica, 2018, 151, 487-488.	0.3	10
56	Ultrasound findings of liver damage in a series of patients consecutively admitted for treatment of alcohol use disorder. Drug and Alcohol Dependence, 2018, 190, 195-199.	1.6	5
57	Cannabinoids: from pot to lab. International Journal of Medical Sciences, 2018, 15, 1286-1295.	1.1	53
58	Cardiovascular disease burden among human immunodeficiency virus-infected individuals. International Journal of Cardiology, 2018, 265, 195-203.	0.8	23
59	Pacientes con trastorno por uso de alcohol: resultados iniciales de un registro multicéntrico en la Red de Trastornos Adictivos-RTA. Estudio CohRTA. Revista De Psicologia De La Salud, 2018, 30, 292.	0.2	1
60	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. Lancet HIV,the, 2017, 4, e251-e259.	2.1	10
61	Long-Term Mortality of Patients with an Alcohol-Related Wernicke–Korsakoff Syndrome. Alcohol and Alcoholism, 2017, 52, 466-471.	0.9	27
62	Folate deficiency in patients seeking treatment of alcohol use disorder. Drug and Alcohol Dependence, 2017, 180, 417-422.	1.6	18
63	Over-expression of CD8+ T-cell activation is associated with decreased CD4+ cells in patients seeking treatment of Alcohol Use Disorder. Drug and Alcohol Dependence, 2017, 180, 7-13.	1.6	7
64	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 311-318.	0.9	12
65	Cannabis as Secondary Drug Is Not Associated With a Greater Risk of Death in Patients With Opiate, Cocaine, or Alcohol Dependence. Journal of Addiction Medicine, 2017, 11, 34-39.	1.4	5
66	Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 126-133.	0.9	32
67	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. Journal of Antimicrobial Chemotherapy, 2017, 72, 2862-2868.	1.3	5
68	A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations. Clinical Infectious Diseases, 2017, 65, 1127-1135.	2.9	10
69	Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World Journal of Hepatology, 2016, 8, 1295.	0.8	37
70	Alcohol Consumption during Pregnancy: Analysis of Two Direct Metabolites of Ethanol in Meconium. International Journal of Molecular Sciences, 2016, 17, 417.	1.8	6
71	Clinical Pharmacology of the Synthetic Cathinone Mephedrone. Current Topics in Behavioral Neurosciences, 2016, 32, 313-331.	0.8	28
72	Wide array of T-cell subpopulation alterations in patients with alcohol use disorders. Drug and Alcohol Dependence, 2016, 162, 124-129.	1.6	9

#	Article	IF	CITATIONS
73	When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 214-221.	0.9	22
74	Impact of Hepatitis C Virus Infection in the Liver-Related Mortality of Patients with Alcohol use Disorder. Journal of Hepatology, 2016, 64, S240-S241.	1.8	1
75	Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes. Medicine (United States), 2016, 95, e5133.	0.4	3
76	Markers of Inflammation and Mortality in a Cohort of Patients With Alcohol Dependence. Medicine (United States), 2015, 94, e607.	0.4	19
77	Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases, 2015, 60, 1262-1268.	2.9	6
78	Impact of hepatitis <scp>C</scp> virus infection on the risk of death of alcoholâ€dependent patients. Journal of Viral Hepatitis, 2015, 22, 18-24.	1.0	19
79	Hepatitis C asociada al abuso de sustancias: nunca tan cerca de un tratamiento sin Interferón. Revista De Psicologia De La Salud, 2015, 27, 141.	0.2	2
80	Hepatitis C associated to substance abuse: ever closer to a treatment without Interferon. Revista De Psicologia De La Salud, 2015, 27, 141-9.	0.2	1
81	The importance of viral blips and duration of therapy initiated in primary infection in maintaining viral control after stopping cART. Journal of the International AIDS Society, 2014, 17, 19820.	1.2	3
82	Antiretroviral Therapy (ART) Use, Human Immunodeficiency Virus (HIV)-1 RNA Suppression, and Medical Causes of Hospitalization Among HIV-Infected Intravenous Drug Users in the Late ART Era. Open Forum Infectious Diseases, 2014, 1, ofu010.	0.4	2
83	Progression of liver fibrosis in <scp>HIV</scp> /hepatitis <scp>C</scp> virusâ€coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline. HIV Medicine, 2014, 15, 203-212.	1.0	20
84	Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study. BMC Infectious Diseases, 2014, 14, 504.	1.3	5
85	Temporal trends in the survival of drug and alcohol abusers according to the primary drug of admission to treatment in Spain. Drug and Alcohol Dependence, 2014, 136, 115-120.	1.6	5
86	Effect of HCV Infection on Cause-Specific Mortality After HIV Seroconversion, Before and After 1997. Gastroenterology, 2013, 144, 751-760.e2.	0.6	76
87	Risk of QTc Prolongation in a Cohort of Opioid-Dependent HIV-Infected Patients on Methadone Maintenance Therapy. Clinical Infectious Diseases, 2013, 57, 1189-1194.	2.9	29
88	All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997–2010. BMC Infectious Diseases, 2013, 13, 382.	1.3	18
89	Prevalence and characteristics of liver disease in alcoholic patients with Wernicke encephalopathy. European Journal of Internal Medicine, 2013, 24, e258.	1.0	0
90	Impact of Medical Comorbidity and Risk of Death in 680 Patients with Alcohol Use Disorders. Alcoholism: Clinical and Experimental Research, 2013, 37, E221-7.	1.4	30

#	Article	IF	Citations
91	Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax, 2013, 68, 207-213.	2.7	26
92	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. Clinical Infectious Diseases, 2013, 56, 888-897.	2.9	88
93	Effectiveness of Antiretroviral Therapy in HIV-1-Infected Active Drug Users Attended in a Drug Abuse Outpatient Treatment Facility Providing a Multidisciplinary Care Strategy. Current HIV Research, 2012, 10, 356-363.	0.2	13
94	Effect of Liver Fibrosis on Long-Term Mortality in HIV/Hepatitis C Virus-Coinfected Individuals Who Are Evaluated to Receive Interferon Therapies in the Highly Active Antiretroviral Therapy Era. AIDS Research and Human Retroviruses, 2012, 28, 1235-1243.	0.5	8
95	28 EFFECT OF HEPATITIS C COINFECTION ON CAUSE-SPECIFIC MORTALITY FOLLOWING HIV SEROCONVERSION IN THE PRE-CART AND CART ERAS. Journal of Hepatology, 2012, 56, S13.	1.8	0
96	Unhealthy Alcohol Use, HIV Infection and Risk of Liver Fibrosis in Drug Users with Hepatitis C. PLoS ONE, 2012, 7, e46810.	1.1	22
97	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. Aids, 2012, 26, 1691-1705.	1.0	31
98	When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries. Annals of Internal Medicine, 2011, 154, 509.	2.0	205
99	Estimated Liver Fibrosis and its Impact on All-Cause Mortality of HCV-Monoinfected and HCV/HIV-Coinfected Drug Users. Current HIV Research, 2011, 9, 256-262.	0.2	16
100	Educational level and HIV disease progression before and after the introduction of HAART: a cohort study in 989 HIV seroconverters in Spain. Sexually Transmitted Infections, 2011, 87, 571-576.	0.8	12
101	Acute coronary syndrome and cocaine use: 8-year prevalence and inhospital outcomes. European Heart Journal, 2011, 32, 1244-1250.	1.0	53
102	Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain. Emerging Infectious Diseases, 2011, 17, 1116-1119.	2.0	6
103	Hepatitis B virus serum profiles in injection drug users and rates of immunization over time in Barcelona: 1987–2006. Drug and Alcohol Dependence, 2010, 110, 234-239.	1.6	10
104	Use of Highly Active Antiretroviral Therapy is Increasing in HIV Positive Severe Drug Users. Current HIV Research, 2010, 8, 641-648.	0.2	8
105	Prospective evaluation of latent tuberculosis with interferon- \hat{l}^3 release assays in drug and alcohol abusers. Epidemiology and Infection, 2009, 137, 1342-1347.	1.0	12
106	Hyaluronic acid, transforming growth factorâ€Î²1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus coâ€infection. Journal of Viral Hepatitis, 2009, 16, 513-518.	1.0	21
107	Paciente con abuso de alcohol, infecci \tilde{A}^3 n por el VIH y hepatitis cr \tilde{A}^3 nica C. Trastornos Adictivos, 2009, 11, 173-179.	0.1	0
108	Accuracy of Simple Biochemical Tests in Identifying Liver Fibrosis in Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis C Virus. Clinical Gastroenterology and Hepatology, 2009, 7, 339-345.	2.4	36

#	Article	IF	CITATIONS
109	Detection of hepatitis C virus antibodies in oral fluid specimens for prevalence studies. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 121-126.	1.3	25
110	Gender Differences in HIV Progression to AIDS and Death in Industrialized Countries: Slower Disease Progression Following HIV Seroconversion in Women. American Journal of Epidemiology, 2008, 168, 532-540.	1.6	82
111	Liver Enzyme Alterations in HCV-Monoinfected and HCV/HIV-Coinfected Patients. Open AIDS Journal, 2008, 2, 82-88.	0.1	6
112	Survival of HIV-Infected Injection Drug Users (IDUs) in the Highly Active Antiretroviral Therapy Era, Relative to Sex- and Age-Specific Survival of HIV-Uninfected IDUs. Clinical Infectious Diseases, 2007, 45, 370-376.	2.9	28
113	Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. Aids, 2007, 21, 2521-2527.	1.0	35
114	Significant reductions of HIV prevalence but not of hepatitis C virus infections in injection drug users from metropolitan Barcelona: 1987–2001. Drug and Alcohol Dependence, 2006, 82, S29-S33.	1.6	37
115	Survival and progression to AIDS in a seroconverter cohort in the post-highly active antiretroviral therapy era: effectiveness goes on. Aids, 2006, 20, 289-291.	1.0	20
116	Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. Aids, 2006, 20, 111-116.	1.0	32
117	Paciente con infecciÃ ³ n por el VIH en tratamiento con metadona. Trastornos Adictivos, 2005, 7, 226-234.	0.1	0
118	Advanced Liver Fibrosis in HIV/HCV-Coinfected Patients on Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2004, 20, 1293-1297.	0.5	44
119	Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting dug users from 1986 to 2001. Journal of Epidemiology and Community Health, 2004, 58, 944-950.	2.0	40
120	Impact of injecting drug use on the interruption of antiretroviral therapies. Journal of Epidemiology and Community Health, 2004, 58, 286-287.	2.0	5
121	Evaluation of a commercial enzyme immunoassay for HIV screening in urine. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 831-835.	1.3	6
122	A parametric survival model with an interval-censored covariate. Statistics in Medicine, 2004, 23, 3159-3175.	0.8	17
123	Trends in Human Immunodeficiency Virus Infection among Drug Users in a Detoxification Unit. Clinical Infectious Diseases, 2003, 37, S404-S409.	2.9	12
124	Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters. Aids, 2003, 17, 353-359.	1.0	89
125	Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. International Journal of Epidemiology, 2002, 31, 951-958.	0.9	64
126	Initiation, changes in use and effectiveness of highly active anti-retroviral therapy in a cohort of injecting drug users. Epidemiology and Infection, 2002, 129, 325-333.	1.0	8

#	Article	IF	Citations
127	Prevalence and distribution of HHV-8 in different subpopulations, with and without HIV infection, in Spain. Aids, 2001, 15, 1167-1174.	1.0	52
128	Mortality of HIV-Positive and HIV-Negative Heroin Abusers as a Function of Duration of Injecting Drug Use. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 332-338.	0.9	3
129	Risk of HIV infection as a function of the duration of intravenous drug use: a non-parametric Bayesian approach. Statistics in Medicine, 2000, 19, 2641-2656.	0.8	12
130	Mortality of HIV-Positive and HIV-Negative Heroin Abusers as a Function of Duration of Injecting Drug Use. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 332-338.	0.9	16
131	Syphilis in injecting drug users: clues for high-risk sexual behaviour in female IDUs. International Journal of STD and AIDS, 1997, 8, 225-228.	0.5	15
132	Epidemiology of HIV-2 infection in Spain. European Journal of Clinical Microbiology and Infectious Diseases, 1996, 15, 383-388.	1.3	9
133	Dandy Walker Syndrome and Associated Polycystic Renal Disease. Nephron, 1992, 60, 253-253.	0.9	1
134	Multifocal splenic abscesses caused by Mycobacterium tuberculosis in HIV-infected drug users. Aids, 1991, 5, 901.	1.0	8
135	Non-Parenteral Transmission of Hepatitis C Virus. International Journal of STD and AIDS, 1991, 2, 449-450.	0.5	0
136	Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV BMJ: British Medical Journal, 1990, 301, 1130-1133.	2.4	118
137	HIV Infection in Not-at-risk Tuberculous Patients in Spain. Chest, 1990, 98, 1548.	0.4	1
138	Natural history of parenteral drug addicts treated in a general hospital. Addiction, 1990, 85, 775-778.	1.7	9
139	Synthetic Peptide Immunoassay in Diagnosis of Primary HIV Infection. Vox Sanguinis, 1990, 58, 228-230.	0.7	8
140	Serological Markers of Human Immunodeficiency Virus Infection in African Patients with AIDS: Are They Different from Markers Found in Patients from Other Countries?. Journal of Infectious Diseases, 1988, 158, 894-894.	1.9	0
141	HIV antigenaemia and prognosis BMJ: British Medical Journal, 1987, 295, 1416-1417.	2.4	0